Transition report pursuant to Rule 13a-10 or 15d-10

Transition Period Comparative Data (Details) - Schedule of statements of operations

v3.22.1
Transition Period Comparative Data (Details) - Schedule of statements of operations - Transition Period Comparative Data [Member] - USD ($)
9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:    
Research and development $ 2,496 $ 2,635
Selling, general and administrative 14,367 11,455
Total operating expenses 16,863 14,090
Loss from operations (16,863) (14,090)
Other income (expense):    
Other income
Other expense (55) (55)
Interest expense (7) (2,665)
Loss on exchange of notes payable for common stock and warrants (1,521)
Gain (loss) on extinguishment of debt 7 (453)
Gain on forgiveness of PPP loan 431  
Change in fair value of warrant liability (1,337)
Change in fair value of derivative liability 39
Total other income (expense) 376 (5,992)
Net loss $ (16,487) $ (20,082)
Net loss per share, basic and diluted: (in Dollars per share) $ (1.13) $ (2.7)
Weighted average shares outstanding, basic and diluted: (in Shares) 14,596,019 7,430,701